Patents Assigned to MedImmune Limited
  • Publication number: 20220204597
    Abstract: The present invention provides a formulation comprising: (i) a monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater (e.g. about 50 mg/ml to about 200 mg/ml) and the ionic excipient is present at a concentration of about 50 to about 150 mM and the formulation has a pH of 5.5 to 6.5.
    Type: Application
    Filed: November 19, 2021
    Publication date: June 30, 2022
    Applicant: MEDIMMUNE LIMITED
    Inventors: Brian LOBO, Deborah Sweet GOLDBERG, Monika Sood SHARMA, Ambarish Umakant SHAH
  • Patent number: 11370801
    Abstract: A compound of formula I and salts and solvates thereof, wherein: R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; where R and R? are independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; R? is a C3-12 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NRN2 (where RN2 is H or C1-4 alkyl), and/or aromatic rings, e.g. benzene or pyridine; Y and Y? are selected from O, S, or NH; R6, R7, R9 are selected from the same groups as R6, R7 and R9 respectively; R11b is selected from OH, ORA, where RA is C1-4 alkyl; and RL is a linker for connection to a cell binding agent.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: June 28, 2022
    Assignee: MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, Stephen John Gregson
  • Patent number: 11352324
    Abstract: A method of synthesising a compound of formula (I): (I) from a compound of formula (II): (II) where R8 is either: (i) ProtO3; or (ii) a group of formula (A1) in formula (I) and (A2) in formula (II): (A1), (A2).
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: June 7, 2022
    Assignee: MEDIMMUNE LIMITED
    Inventors: Arnaud Charles Tiberghien, Andrew Duncan Campbell, Jeremy Parker
  • Patent number: 11318211
    Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCS).
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: May 3, 2022
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITED
    Inventors: Jay Marshall Feingold, David Rodney Ungar
  • Patent number: 11286294
    Abstract: The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.
    Type: Grant
    Filed: June 18, 2021
    Date of Patent: March 29, 2022
    Assignee: MEDIMMUNE LIMITED
    Inventors: Brian Lobo, Deborah Goldberg
  • Patent number: 11286297
    Abstract: Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: March 29, 2022
    Assignee: MEDIMMUNE LIMITED
    Inventors: Maria Groves, Suzanne Gustavsson, Kina Höglund, Chris Lloyd, Adrian Nickson, Camilla Niva, Sylvia Simon, David Lowne, Fraser Welsh, Per-Ola Freskgärd
  • Patent number: 11230584
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: January 25, 2022
    Assignee: MEDIMMUNE LIMITED
    Inventors: Balaji Agoram, Madeleine Antonsson, Maria A. Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • Patent number: 11203633
    Abstract: This disclosure relates to polynucleotides encoding antibodies or antigen binding fragments thereof that bind to Pseudomonas PcrV as well as vectors and host cells comprising the same.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: December 21, 2021
    Assignee: MedImmune Limited
    Inventors: Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Ralph Minter, Sandrine Guillard, Steven Rust, Mladen Tomich, Vignesh Venkatraman, Reena Varkey, Li Peng, Melissa Damschroder, Partha S. Chowdhury, Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Godfrey Rainey, Cuihua Gao
  • Patent number: 11192948
    Abstract: The disclosure generally provides compositions and methods that are useful in the treatment of cancer. More specifically, the methods and compositions may be used to detect, quantify, inhibit, kill, differentiate, or eliminate cancer stem cells (CSCs) and may be used in the treatment of cancers associated with CSCs, and particularly cancers and CSCs that express LOX1.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: December 7, 2021
    Assignee: MedImmune Limited
    Inventors: Elaine M. Hurt, Ralph Minter, Steven Rust, Alan Sandercock, Sotirios Karathanasis
  • Patent number: 11173124
    Abstract: The present invention provides formulations for oral administration of GLP-1 peptide analogs, methods of making such formulations, and methods of treatment using such formulations.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: November 16, 2021
    Assignee: MedImmune Limited
    Inventors: Sergei Pechenov, Puneet Tyagi, Janardhanan Anand Subramony
  • Patent number: 11160872
    Abstract: A conjugate of formula (T): Ab-(DL)p wherein: Ah is an antibody that hinds to AXL; DL is formula (A).
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: November 2, 2021
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITED
    Inventor: Patricius Hendrikus Cornelis Van Berkel
  • Patent number: 11135303
    Abstract: A conjugate of formula (A): where Y is selected from a single bond, and a group of formulae A1 or A2: where N shows where the group binds to the N10 of the PBD moiety; RL1 and RL2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropylene group; CBA represents a cell binding agent; Q is independently selected from O, S and NH; R11 is either H, or R or, where Q is O, SO3M, where M is a metal cation.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: October 5, 2021
    Assignee: Medimmune Limited
    Inventors: John A. Flygare, Janet L. Gunzner-Toste, Thomas Pillow, Philip Wilson Howard, Luke Masterson
  • Patent number: 11136396
    Abstract: The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. The present invention also provides compositions, formulations, and unit dosage forms comprising the purified polypeptide or immunoconjugate.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: October 5, 2021
    Assignee: MedImmune Limited
    Inventors: Thomas Linke, William K. Wang, Ambarish Shah, Hasige Sathish, Alan Hunter, Christopher Thompson
  • Patent number: 11078284
    Abstract: This disclosure provides LOX1 (LOX1) binding proteins such as anti-LOX1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the LOX1-binding proteins provided herein, inhibit, or antagonize LOX1 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia (e.g., myocardial ischemia), infarction (e.g., myocardial infarction), acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, inflammation (e.g., chronic inflammation), angiogenesis, preeclampsia, cancer and other LOX1-mediated diseases and conditions.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: August 3, 2021
    Assignee: MedImmune Limited
    Inventors: Andrew Buchanan, Matthieu Chodorge, Peter Cariuk, Johanna Husmark, Clare Balendran, Deepesh Pandey, Fumin Chang, Daniel E. Berkowitz, Lewis H. Romer
  • Patent number: 11066461
    Abstract: A method for preventing or treating nosocomial diseases, e.g., diseases caused by Pseudomonas aeruginosa, is provided. The method includes administering to a susceptible human subject a specified dose of a bispecific antibody that specifically binds Pseudomonas aeruginosa Psl and PcrV.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: July 20, 2021
    Assignee: MEDIMMUNE LIMITED
    Inventors: Hasan Jafri, Antonio Digiandomenico, Michael McCarthy, Xiang-Qing Yu, Charles K. Stover, Brian Bishop
  • Patent number: 11065336
    Abstract: In some embodiments, the disclosure provides for a conjugate comprising: a) a peptide that competes with an Fc fragment of an IgG for binding to an Fc receptor; and b) a targeting moiety that targets molecular aggregates. In some embodiments, the disclosure provides for methods of using the conjugates for treating a disease or disorder associated with aggregate formation.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: July 20, 2021
    Assignee: MEDIMMUNE LIMITED
    Inventors: Damian C. Crowther, Maria Herva, Roland Bürli, Lutz Jermutus
  • Patent number: 11053307
    Abstract: This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF? antagonist. The NGF antagonist and the TNF? antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF? antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF? antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF? antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF? antagonist administered alone.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: July 6, 2021
    Assignee: MedImmune Limited
    Inventors: Darren Schofield, Matthew Alexander Sleeman, Iain Patrick Chessell, Jonathan Hatcher, David Lowe
  • Publication number: 20210147531
    Abstract: The present invention relates to antibodies having activity against a vascular endothelial growth factor (VEGF), and methods of making and using such antibodies.
    Type: Application
    Filed: January 19, 2021
    Publication date: May 20, 2021
    Applicant: MEDIMMUNE LIMITED
    Inventors: Ching Ching Leow, Nazzareno Dimasi, Karen Coffman, Ping Tsui, Changshou Gao, Mario A. Cepeda, Adrian Schwartz Mittelman
  • Patent number: 10994023
    Abstract: A compound which is either A: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: May 4, 2021
    Assignee: MEDIMMUNE LIMITED
    Inventor: Philip Wilson Howard
  • Patent number: 10954308
    Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: March 23, 2021
    Assignee: MEDIMMUNE LIMITED
    Inventors: Andrew Buchanan, Sven Nylander, Mark Penney, Philip Newton, Feenagh Keyes, Tord Inghardt